Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

What will it take to eliminate drug-resistant tuberculosis?

Kendall EA, Sahu S, Pai M, Fox GJ, Varaine F, Cox H, Cegielski JP, Mabote L, Vassall A, Dowdy DW.

Int J Tuberc Lung Dis. 2019 May 1;23(5):535-546. doi: 10.5588/ijtld.18.0217.

PMID:
31097060
2.

Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.

Al-Shaer MH, Alghamdi WA, Alsultan A, An G, Ahmed S, Alkabab Y, Banu S, Barbakadze K, Houpt E, Kipiani M, Mikiashvili L, Cegielski JP, Kempker RR, Heysell SK, Peloquin CA.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00279-19. doi: 10.1128/AAC.00279-19. Print 2019 Jul.

3.

Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis.

Alghamdi WA, Alsultan A, Al-Shaer MH, An G, Ahmed S, Alkabab Y, Banu S, Barbakadze K, Houpt E, Kipiani M, Mikiashvili L, Schmidt S, Heysell SK, Kempker RR, Cegielski JP, Peloquin CA.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e00055-19. doi: 10.1128/AAC.00055-19. Print 2019 May.

4.

Loss to follow-up among patients receiving anti-tuberculosis treatment, Haiti, 2011-2015.

Schnaubelt ER, Charles M, Richard M, Fitter DL, Morose W, Cegielski JP.

Public Health Action. 2018 Dec 21;8(4):154-161. doi: 10.5588/pha.18.0043.

5.

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.

Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilbrun SC, Walsh K, Westenhouse J, Yew WW, Yim JJ, Zetola NM, Zignol M, Menzies D.

Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1. Review.

6.

Multidrug-Resistant Tuberculosis in the End Tuberculosis EraMultidrug-Resistant Tuberculosis in the End Tuberculosis Era.

Cegielski JP.

Rev Peru Med Exp Salud Publica. 2018 Jan-Mar;35(1):110-117. doi: 10.17843/rpmesp.2018.351.3618. Spanish, English.

7.

Low body mass index and latent tuberculous infection: a systematic review and meta-analysis.

Saag LA, LaValley MP, Hochberg NS, Cegielski JP, Pleskunas JA, Linas BP, Horsburgh CR.

Int J Tuberc Lung Dis. 2018 Apr 1;22(4):358-365. doi: 10.5588/ijtld.17.0558.

PMID:
29562981
8.

Factors Associated With All-Cause Mortality Among Patients With Multidrug-Resistant Tuberculosis-United States, 1993-2013.

Salinas JL, Armstrong LR, Silk BJ, Haddad MB, Cegielski JP.

Clin Infect Dis. 2017 Nov 13;65(11):1924-1926. doi: 10.1093/cid/cix667.

PMID:
29020169
9.

Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.

Cavanaugh JS, Jou R, Wu MH, Dalton T, Kurbatova E, Ershova J, Cegielski JP; Global PETTS Investigators.

J Antimicrob Chemother. 2017 Jun 1;72(6):1678-1687. doi: 10.1093/jac/dkx022.

10.

Treatment Outcomes for Patients with Extensively Drug-Resistant Tuberculosis, KwaZulu-Natal and Eastern Cape Provinces, South Africa.

Kvasnovsky CL, Cegielski JP, van der Walt ML.

Emerg Infect Dis. 2016 Sep;22(9). doi: 10.3201/eid2209.160084. Erratum in: Emerg Infect Dis. 2016 Nov;22(11):2028.

11.

Associations Between Vitamin D Level and Hospitalizations With and Without an Infection in a National Cohort of Medicare Beneficiaries.

Kempker JA, Magee MJ, Cegielski JP, Martin GS.

Am J Epidemiol. 2016 May 15;183(10):920-9. doi: 10.1093/aje/kwv306. Epub 2016 Apr 18.

12.

Impact of HIV on mortality among patients treated for tuberculosis in Lima, Peru: a prospective cohort study.

Velásquez GE, Cegielski JP, Murray MB, Yagui MJ, Asencios LL, Bayona JN, Bonilla CA, Jave HO, Yale G, Suárez CZ, Sanchez E, Rojas C, Atwood SS, Contreras CC, Santa Cruz J, Shin SS.

BMC Infect Dis. 2016 Feb 1;16:45. doi: 10.1186/s12879-016-1375-8.

13.

Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study.

Yuen CM, Kurbatova EV, Tupasi T, Caoili JC, Van Der Walt M, Kvasnovsky C, Yagui M, Bayona J, Contreras C, Leimane V, Ershova J, Via LE, Kim H, Akksilp S, Kazennyy BY, Volchenkov GV, Jou R, Kliiman K, Demikhova OV, Vasilyeva IA, Dalton T, Cegielski JP.

PLoS Med. 2015 Dec 29;12(12):e1001932. doi: 10.1371/journal.pmed.1001932. eCollection 2015 Dec.

14.

Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance.

Cegielski JP, Kurbatova E, van der Walt M, Brand J, Ershova J, Tupasi T, Caoili JC, Dalton T, Contreras C, Yagui M, Bayona J, Kvasnovsky C, Leimane V, Kuksa L, Chen MP, Via LE, Hwang SH, Wolfgang M, Volchenkov GV, Somova T, Smith SE, Akksilp S, Wattanaamornkiet W, Kim HJ, Kim CK, Kazennyy BY, Khorosheva T, Kliiman K, Viiklepp P, Jou R, Huang AS, Vasilyeva IA, Demikhova OV; Global PETTS Investigators, Lancaster J, Odendaal R, Diem L, Perez TC, Gler T, Tan K, Bonilla C, Jave O, Asencios L, Yale G, Suarez C, Walker AT, Norvaisha I, Skenders G, Sture I, Riekstina V, Cirule A, Sigman E, Cho SN, Cai Y, Eum S, Lee J, Park S, Jeon D, Shamputa IC, Metchock B, Kuznetsova T, Akksilp R, Sitti W, Inyapong J, Kiryanova EV, Degtyareva I, Nemtsova ES, Levina K, Danilovits M, Kummik T, Lei YC, Huang WL, Erokhin VV, Chernousova LN, Andreevskaya SN, Larionova EE, Smirnova TG.

Clin Infect Dis. 2016 Feb 15;62(4):418-430. doi: 10.1093/cid/civ910. Epub 2015 Oct 27.

15.

Epidemiology of Primary Multidrug-Resistant Tuberculosis, Vladimir Region, Russia.

Ershova JV, Volchenkov GV, Kaminski DA, Somova TR, Kuznetsova TA, Kaunetis NV, Cegielski JP, Kurbatova EV.

Emerg Infect Dis. 2015 Nov;21(11):2048-51. doi: 10.3201/eid2111.150813.

16.

Risk factors for acquisition of drug resistance during multidrug-resistant tuberculosis treatment, Arkhangelsk Oblast, Russia, 2005-2010.

Smith SE, Ershova J, Vlasova N, Nikishova E, Tarasova I, Eliseev P, Maryandyshev AO, Shemyakin IG, Kurbatova E, Cegielski JP.

Emerg Infect Dis. 2015 Jun;21(6):1002-11. doi: 10.3201/eid2106.141907.

17.

Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries.

Kurbatova EV, Dalton T, Ershova J, Tupasi T, Caoili JC, Van Der Walt M, Kvasnovsky C, Yagui M, Bayona J, Contreras C, Leimane V, Via LE, Kim H, Akksilp S, Kazennyy BY, Volchenkov GV, Jou R, Kliiman K, Demikhova OV, Cegielski JP.

Emerg Infect Dis. 2015 Jun;21(6):977-83. doi: 10.3201/eid2106.141329.

18.

Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies.

Kurbatova EV, Cegielski JP, Lienhardt C, Akksilp R, Bayona J, Becerra MC, Caoili J, Contreras C, Dalton T, Danilovits M, Demikhova OV, Ershova J, Gammino VM, Gelmanova I, Heilig CM, Jou R, Kazennyy B, Keshavjee S, Kim HJ, Kliiman K, Kvasnovsky C, Leimane V, Mitnick CD, Quelapio I, Riekstina V, Smith SE, Tupasi T, van der Walt M, Vasilyeva IA, Via LE, Viiklepp P, Volchenkov G, Walker AT, Wolfgang M, Yagui M, Zignol M.

Lancet Respir Med. 2015 Mar;3(3):201-9. doi: 10.1016/S2213-2600(15)00036-3. Epub 2015 Feb 26.

19.

Reply to Soman et al, Alffenaar et al, Metcalfe et al, and Raoult.

Cegielski JP, Chen MP, Tupasi TE, Leimane V, Volchenkov GV; Global Preserving Effective TB Treatment Study Investigators.

Clin Infect Dis. 2015 Mar 15;60(6):971-3. doi: 10.1093/cid/ciu1150. Epub 2014 Dec 19. No abstract available.

20.

Annual risk of tuberculous infection measured using serial skin testing, Orel Oblast, Russia, 1991-2005.

Yuen CM, Krapivina TM, Kazennyy BY, Kiryanova EV, Aksenova VA, Gordina A, Finlay AM, Cegielski JP.

Int J Tuberc Lung Dis. 2015 Jan;19(1):39-43. doi: 10.5588/ijtld.14.0445.

PMID:
25519788
21.

Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.

Cegielski JP, Dalton T, Yagui M, Wattanaamornkiet W, Volchenkov GV, Via LE, Van Der Walt M, Tupasi T, Smith SE, Odendaal R, Leimane V, Kvasnovsky C, Kuznetsova T, Kurbatova E, Kummik T, Kuksa L, Kliiman K, Kiryanova EV, Kim H, Kim CK, Kazennyy BY, Jou R, Huang WL, Ershova J, Erokhin VV, Diem L, Contreras C, Cho SN, Chernousova LN, Chen MP, Caoili JC, Bayona J, Akksilp S; Global Preserving Effective TB Treatment Study (PETTS) Investigators.

Clin Infect Dis. 2014 Oct 15;59(8):1049-63. doi: 10.1093/cid/ciu572. Epub 2014 Jul 23.

22.

Eliminating tuberculosis one neighborhood at a time.

Cegielski JP, Griffith DE, McGaha PK, Wolfgang M, Robinson CB, Clark PA, Hassell WL, Robison VA, Walker KP Jr, Wallace C.

Am J Public Health. 2014 Apr;104 Suppl 2:S214-33. doi: 10.2105/AJPH.2012.300781r.

23.

Mortality among tuberculosis patients with acquired resistance to second-line antituberculosis drugs--United States, 1993-2008.

Ershova JV, Kurbatova EV, Moonan PK, Cegielski JP.

Clin Infect Dis. 2014 Aug 15;59(4):465-72. doi: 10.1093/cid/ciu372. Epub 2014 May 20.

24.

Association between Mycobacterium tuberculosis complex phylogenetic lineage and acquired drug resistance.

Yuen CM, Kurbatova EV, Click ES, Cavanaugh JS, Cegielski JP.

PLoS One. 2013 Dec 23;8(12):e83006. doi: 10.1371/journal.pone.0083006. eCollection 2013.

25.

[Eliminating tuberculosis one neighborhood at a time].

Cegielski JP, Griffith DE, McGaha PK, Wolfgang M, Robinson CB, Clark PA, Hassell WL, Robison VA, Walker KP, Wallace C.

Rev Panam Salud Publica. 2013 Oct;34(4):284-94. Spanish.

PMID:
24301742
26.

Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009.

Kurbatova EV, Cavanaugh JS, Dalton T, Click ES, Cegielski JP.

Clin Infect Dis. 2013 Oct;57(8):1081-93. doi: 10.1093/cid/cit452. Epub 2013 Jul 9.

27.

Clinical characteristics, drug resistance, and treatment outcomes among tuberculosis patients with diabetes in Peru.

Magee MJ, Bloss E, Shin SS, Contreras C, Huaman HA, Ticona JC, Bayona J, Bonilla C, Yagui M, Jave O, Cegielski JP.

Int J Infect Dis. 2013 Jun;17(6):e404-12. doi: 10.1016/j.ijid.2012.12.029. Epub 2013 Feb 22.

28.

Performance of Cepheid ® Xpert MTB/RIF ® and TB-Biochip ® MDR in two regions of Russia with a high prevalence of drug-resistant tuberculosis.

Kurbatova EV, Kaminski DA, Erokhin VV, Volchenkov GV, Andreevskaya SN, Chernousova LN, Demikhova OV, Ershova JV, Kaunetis NV, Kuznetsova TA, Larionova EE, Smirnova TG, Somova TR, Vasilieva IA, Vorobieva AV, Zolkina SS, Cegielski JP.

Eur J Clin Microbiol Infect Dis. 2013 Jun;32(6):735-43. doi: 10.1007/s10096-012-1798-0. Epub 2012 Dec 22.

29.

Prevalence of anti-tuberculosis drug resistance in foreign-born tuberculosis cases in the U.S. and in their countries of origin.

Taylor AB, Kurbatova EV, Cegielski JP.

PLoS One. 2012;7(11):e49355. doi: 10.1371/journal.pone.0049355. Epub 2012 Nov 7.

30.

Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis.

Kurbatova EV, Gammino VM, Bayona J, Becerra MC, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riekstina V, Taylor A, Viiklepp P, Zignol M, Cegielski JP.

Int J Tuberc Lung Dis. 2012 Oct;16(10):1335-43. doi: 10.5588/ijtld.11.0811.

PMID:
23107633
31.

Eliminating tuberculosis one neighborhood at a time.

Cegielski JP, Griffith DE, McGaha PK, Wolfgang M, Robinson CB, Clark PA, Hassell WL, Robison VA, Walker KP Jr, Wallace C.

Am J Public Health. 2013 Jul;103(7):1292-300. doi: 10.2105/AJPH.2012.300781. Epub 2012 Oct 18.

32.

Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru.

Shin SS, Asencios L, Yagui M, Yale G, Suárez C, Bayona J, Bonilla C, Jave O, Contreras CC, Atwood S, Blaya JA, Ershova J, Cegielski JP.

Int J Tuberc Lung Dis. 2012 Nov;16(11):1538-43. doi: 10.5588/ijtld.12.0071. Epub 2012 Sep 14.

33.

Acquired resistance to second-line drugs among persons with tuberculosis in the United States.

Ershova JV, Kurbatova EV, Moonan PK, Cegielski JP.

Clin Infect Dis. 2012 Dec;55(12):1600-7. doi: 10.1093/cid/cis748. Epub 2012 Aug 31.

34.

Impact of second-line drug resistance on tuberculosis treatment outcomes in the United States: MDR-TB is bad enough.

Althomsons SP, Cegielski JP.

Int J Tuberc Lung Dis. 2012 Oct;16(10):1331-4. doi: 10.5588/ijtld.11.0812. Epub 2012 Aug 3.

35.

Nutritional risk factors for tuberculosis among adults in the United States, 1971-1992.

Cegielski JP, Arab L, Cornoni-Huntley J.

Am J Epidemiol. 2012 Sep 1;176(5):409-22. doi: 10.1093/aje/kws007. Epub 2012 Jul 11.

36.

Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects.

Kurbatova EV, Taylor A, Gammino VM, Bayona J, Becerra M, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riekstina V, Viiklepp P, Zignol M, Cegielski JP.

Tuberculosis (Edinb). 2012 Sep;92(5):397-403. doi: 10.1016/j.tube.2012.06.003. Epub 2012 Jul 10.

37.

Outcomes and follow-up of patients treated for multidrug-resistant tuberculosis in Orel, Russia, 2002-2005.

Cavanaugh JS, Kazennyy BY, Nguyen ML, Kiryanova EV, Vitek E, Khorosheva TM, Nemtsova E, Cegielski JP.

Int J Tuberc Lung Dis. 2012 Aug;16(8):1069-74. doi: 10.5588/ijtld.11.0696. Epub 2012 Jun 11.

38.

Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs.

Kurbatova EV, Cavanaugh JS, Shah NS, Wright A, Kim H, Metchock B, Van Deun A, Barrera L, Boulahbal F, Richter E, Martín-Casabona N, Arias F, Zemanova I, Drobniewski F, Santos Silva A, Coulter C, Lumb R, Cegielski JP.

Int J Tuberc Lung Dis. 2012;16(3):355-7. doi: 10.5588/ijtld.11.0542.

39.

Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis.

Smith SE, Kurbatova EV, Cavanaugh JS, Cegielski JP.

Int J Tuberc Lung Dis. 2012 Feb;16(2):203-5. doi: 10.5588/ijtld.11.0445.

40.

Frequency and type of microbiological monitoring of multidrug-resistant tuberculosis treatment.

Kurbatova EV, Gammino VM, Bayona J, Becerra M, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riekstina V, Taylor A, Viiklepp P, Zignol M, Cegielski JP.

Int J Tuberc Lung Dis. 2011 Nov;15(11):1553-5, i. doi: 10.5588/ijtld.11.0101.

PMID:
22008772
41.

Targeted drug-resistance testing strategy for multidrug-resistant tuberculosis detection, Lima, Peru, 2005-2008.

Velásquez GE, Yagui M, Cegielski JP, Asencios L, Bayona J, Bonilla C, Jave HO, Yale G, Suárez C, Atwood S, Contreras CC, Shin SS.

Emerg Infect Dis. 2011 Mar;17(3):432-40. doi: 10.3201/eid1703.101553.

42.

Extensively drug-resistant TB in Eastern Cape, South Africa: high mortality in HIV-negative and HIV-positive patients.

Kvasnovsky CL, Cegielski JP, Erasmus R, Siwisa NO, Thomas K, der Walt ML.

J Acquir Immune Defic Syndr. 2011 Jun 1;57(2):146-52. doi: 10.1097/QAI.0b013e31821190a3.

PMID:
21297482
43.

Extensively drug-resistant tuberculosis: "there must be some kind of way out of here".

Cegielski JP.

Clin Infect Dis. 2010 May 15;50 Suppl 3:S195-200. doi: 10.1086/651491. Review.

PMID:
20397948
44.

Global policies and practices for managing persons exposed to multidrug-resistant tuberculosis.

Cain KP, Nelson LJ, Cegielski JP.

Int J Tuberc Lung Dis. 2010 Mar;14(3):269-74.

PMID:
20132616
45.

Extensively drug-resistant tuberculosis in the United States, 1993-2007.

Shah NS, Pratt R, Armstrong L, Robison V, Castro KG, Cegielski JP.

JAMA. 2008 Nov 12;300(18):2153-60. doi: 10.1001/jama.300.18.2153.

PMID:
19001626
46.

A web-based laboratory information system to improve quality of care of tuberculosis patients in Peru: functional requirements, implementation and usage statistics.

Blaya JA, Shin SS, Yagui MJ, Yale G, Suarez CZ, Asencios LL, Cegielski JP, Fraser HS.

BMC Med Inform Decis Mak. 2007 Oct 28;7:33.

47.

HIV infection and multidrug-resistant tuberculosis: the perfect storm.

Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, Castro KG, Weyer K.

J Infect Dis. 2007 Aug 15;196 Suppl 1:S86-107. Review.

PMID:
17624830
48.

Origin of the term XDR-TB.

Holtz TH, Cegielski JP.

Eur Respir J. 2007 Aug;30(2):396. No abstract available.

49.

Worldwide emergence of extensively drug-resistant tuberculosis.

Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, Martín-Casabona N, Drobniewski F, Gilpin C, Havelková M, Lepe R, Lumb R, Metchock B, Portaels F, Rodrigues MF, Rüsch-Gerdes S, Van Deun A, Vincent V, Laserson K, Wells C, Cegielski JP.

Emerg Infect Dis. 2007 Mar;13(3):380-7.

50.

Multidrug-resistant tuberculosis management in resource-limited settings.

Nathanson E, Lambregts-van Weezenbeek C, Rich ML, Gupta R, Bayona J, Blöndal K, Caminero JA, Cegielski JP, Danilovits M, Espinal MA, Hollo V, Jaramillo E, Leimane V, Mitnick CD, Mukherjee JS, Nunn P, Pasechnikov A, Tupasi T, Wells C, Raviglione MC.

Emerg Infect Dis. 2006 Sep;12(9):1389-97.

Supplemental Content

Loading ...
Support Center